Navigation Links
Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch
Date:9/26/2011

), potential for new opportunities beyond initial indications and corporate stability."

About the Hepatitis C Virus

Hepatitis C is a liver disease affecting over 170 million people worldwide. The virus is spread through direct contact with the blood of an infected person. Hepatitis C increases a person's risk of developing chronic liver disease, cirrhosis, liver cancer and death. Liver disease associated with HCV infection is growing rapidly, and there is an acute need for new therapies that are safer and more effective. Specifically targeted antiviral therapies for HCV, such as NS3/4a protease and NS5A inhibitors, may have the potential to increase the proportion of patients in whom the virus can be eradicated.

About Enanta

Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the infectious disease field. Enanta is developing novel protease, NS5A, nucleoside(tide) polymerase, and cyclophilin-based inhibitors targeted against the Hepatitis C virus (HCV). Additionally, the Company has created a new class of macrolide antibiotics, called Bicyclolides, which overcomes bacterial resistance. Antibacterial focus areas include overcoming resistance to superbugs, treating respiratory tract infections, and developing intravenous and oral treatments for hospital and community MRSA infections. Enanta is a privately held company headquartered in Watertown, Mass. Enanta's news releases and other information are available on the company's web site at www.enanta.com.

For Enanta Investor Relations, please contact:
Paul Mellett
617-607-0761

For Enanta Public Relations, please contact MacDougall Biomedical Communications:
Kari Watson
508-647-0209 or
'/>"/>

SOURCE Enanta Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
2. Modulation of inhibitory output is key function of antiobesity hormone
3. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
4. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
5. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
6. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
7. S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
8. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
9. Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting
10. Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry
11. CalciMedica Initiates Phase I Clinical Trial of First CRAC Channel Inhibitor (CCI) for Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015   Intrexon Corporation (NYSE: ... and second quarter 2015 financial results after the market ... Company will host a conference call at 5:30 PM ... business update. The conference call may be ... and asking to join the "Intrexon Corporation Call."  Participants ...
(Date:7/31/2015)... 2015 In today,s fast changing healthcare ... drive positive health outcomes, improve profitability and enhance ... care in their communities. At ThoughtSpot 2015, ... AmerisourceBergen announced a new set of innovative capabilities ... and help independent pharmacies endure the industry,s most ...
(Date:7/30/2015)... ... ... Ralco is honored to announce that it is the primary sponsor of the ... in Marshall. The Ralco Enrichment Center is an interactive experience where the public can ... lives. This unique exhibit also features a birthing center for fair goers to watch ...
(Date:7/30/2015)... ... 30, 2015 , ... The 2015 Market Research Report on the Global ... the global Propanol market with a focus on the Chinese situation. Major companies included ... Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , ...
Breaking Biology Technology:Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3
... NEW YORK, Aug. 4 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... at 8:30 a.m. EDT to discuss the second quarter 2009 financial results ... Executive Officer of the Company, will host the call. Keryx will ... be issued prior to the call. , , In ...
... SHANGHAI, Aug. 4 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., ... that it has moved its drug discovery collaboration with ... fully integrated,services in the areas of DMPK, pharmacology and ... joint project team from both sides will,work closely together ...
... , , , VENLO, The Netherlands, Aug. 4 ... second quarter 2009 financial results call. The Webcast will take place at 9:30 a.m. ... and Chief Executive Officer, and Roland Sackers, Chief Financial Officer. , , ... quarter 2009 financial results call, When: 9:30 ...
Cached Biology Technology:Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT 2Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level 2Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Second Quarter 2009 Financial Results Call Set for August 11 2
(Date:7/31/2015)... julio de 2015 La 10 th International ... medio de BGI del 22 al 25 de octubre de 2015 ... Este año, la conferencia celebra su décimo aniversario. Desde su ... una de las reuniones anuales más influyentes del mundo en ... más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/27/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Huawei has selected the Synaptics ® ... stylish smartwatch. Huawei chose the state-of-the-art ClearPad capacitive ... and highly responsive human interface qualities such as ... required a classic round watch face and Synaptics ...
(Date:7/21/2015)... July 21, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... announces that it has filed provisional patent 62/192218 ... This invention highlights next generation ... an account, but also the user using unique ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... research shows that teathe second most consumed beverage in the ... of cancer and type 2 diabetes. New research shows tea ... a healthy weight, improve bone health and activate areas of ... The December 2013 issue of the American Journal of ...
... from industrial plants rather than releasing its warming potential ... a commercial reality. Several large chemical companies in Germany and ... to an article in Chemical & Engineering News , ... Scott, C&EN,s senior editor for Europe, points out that German ...
... MD (November 6, 2013) A new study shows that ... mid-Atlantic is making an impact on the quality of the ... by scientists at the University of Maryland Center for Environmental ... oxide from coal-fired power plants declined in response to the ...
Cached Biology News:New research shows tea may help promote weight loss, improve heart health and slow progression of prostate cancer 2New research shows tea may help promote weight loss, improve heart health and slow progression of prostate cancer 3New research shows tea may help promote weight loss, improve heart health and slow progression of prostate cancer 4New research shows tea may help promote weight loss, improve heart health and slow progression of prostate cancer 5Clean Air Act has led to improved water quality in the Chesapeake Bay watershed 2
The SmartSpec printer paper is used to record data generated by the SmartSpec Plus spectrophotometer. Supplied as 5 packs....
... Ciphergen's ProteinChip arrays have been developed ... biological samples. A variety of ProteinChip ... proteins according to their unique biochemical ... spots, allowing side-by-side sample comparison, and ...
... SR-101 Labeled Substrates (red fluorescence; Ex=590 ... serine protease activation • No lysing, ... Kits utilize cell-permeable, fluorescently labeled inhibitors ... chymotrypsin-like activity in whole living cells. ...
... with FAM-Labeled Substrate (green fluorescence; Ex=488 ... serine protease activation • No lysing, ... Kits utilize cell-permeable, fluorescently labeled inhibitors ... chymotrypsin-like activity in whole living cells. ...
Biology Products: